Market closed
Ardelyx/$ARDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ardelyx
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Ticker
$ARDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
395
Website
Ardelyx Metrics
BasicAdvanced
$1B
-
-$0.17
0.85
-
Price and volume
Market cap
$1B
Beta
0.85
52-week high
$9.33
52-week low
$4.02
Average daily volume
4.6M
Financial strength
Current ratio
4.58
Quick ratio
3.955
Long term debt to equity
102.374
Total debt to equity
103.275
Interest coverage (TTM)
-1.39%
Management effectiveness
Return on assets (TTM)
-4.76%
Return on equity (TTM)
-23.01%
Valuation
Price to revenue (TTM)
2.997
Price to book
5.84
Price to tangible book (TTM)
5.84
Price to free cash flow (TTM)
-21.819
Growth
Revenue change (TTM)
168.06%
Earnings per share change (TTM)
-44.77%
3-year revenue growth (CAGR)
220.89%
3-year earnings per share growth (CAGR)
-52.17%
What the Analysts think about Ardelyx
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Ardelyx Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Ardelyx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Ardelyx News
AllArticlesVideos
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
GlobeNewsWire·2 days ago
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
GlobeNewsWire·2 weeks ago
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ardelyx stock?
Ardelyx (ARDX) has a market cap of $1B as of April 12, 2025.
What is the P/E ratio for Ardelyx stock?
The price to earnings (P/E) ratio for Ardelyx (ARDX) stock is 0 as of April 12, 2025.
Does Ardelyx stock pay dividends?
No, Ardelyx (ARDX) stock does not pay dividends to its shareholders as of April 12, 2025.
When is the next Ardelyx dividend payment date?
Ardelyx (ARDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ardelyx?
Ardelyx (ARDX) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.